Tel Aviv Sourasky breast cancer patients already benefit from new protocol

The major study reverberated around the world earlier this week.

By
June 4, 2018 20:55
2 minute read.
Nurse

A women speaks to a nurse (illustrative photo). (photo credit: INGIMAGE)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Oncologists at Tel Aviv Sourasky Medical Center are already treating women over 50 with early-stage breast cancer, who have estrogen-positive tumors, with biological drugs instead of chemotherapy.

The efficacy of such therapy – allowing faster recovery, with a higher quality of life and fewer severe side effects – has recently been proven effective by the TAILORx study, just presented at a meeting of the American Society of Clinical Oncology.

Be the first to know - Join our Facebook page.


The major study, just published in The New England Journal of Medicine, reverberated around the world earlier this week. A 21-gene-expression test called OncotypeDX measures the activity of genes involved in the recurrence of breast cancer and determines whether a patient will be better off with or without chemotherapy, which is toxic to healthy cells. The test is subsidized if a woman has a supplementary public health fund policy or private insurance.

The major progressive study was launched 12 years ago and eventually encompassed 10,253 women aged 18 to 75. Fully 70% of the participants had scores of 11 to 25 on the gene test and underwent both surgery to remove the malignancy and radiation. They were then assigned randomly to get either endocrine treatment plus chemotherapy or the hormonal treatment alone. The women were followed up for an average of more than seven years.

The researchers found that chemotherapy for this age group and condition had no advantage, as both groups did equally well. After nine years, 93.9% in the endocrine-only group were still alive; 93.8% of those who got the dual treatment also survived.

In the endocrine group, 83.3 % were free of invasive cancer compared with 84.3% who were given both treatments. Chemotherapy was recommended for women under 50, however; the results showed that some of those women would benefit from chemo even if the OncotypeDX test had low results; why this is so is not yet understood by oncologists.

“We at the breast unit in the oncology system at Sourasky’s Ichilov Hospital are working according to the principles outlined in this study and similar studies done in the past,” said Dr. Amir Sonnenblick, head of the breast cancer unit at Sourasky. “Indeed, most of the patients treated with estrogen receptor-positive tumors avoid chemotherapy and make do with hormonal therapy. Today, most of our breast cancer patients who are positive for the receptors are able to avoid chemotherapy after surgery to remove the tumor.”


JPOST VIDEOS THAT MIGHT INTEREST YOU:

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

HomeBiogas co-founders (left to right): Chief financial officer Erez Lanzer, chief executive Oshik E
November 19, 2018
World toilet day: Israeli biogas company transforms human waste into fuel

By EYTAN HALON